Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study
| Title: | Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study |
|---|---|
| Authors: | Ziemssen, TjalfAff1, IDs4026302000749x_cor1; Bass, Ann D.Aff2; Berkovich, ReginaAff3, Aff4; Comi, GiancarloAff5; Eichau, SaraAff6; Hobart, JeremyAff7; Hunter, Samuel FAff8; LaGanke, ChristopherAff9; Limmroth, VolkerAff10; Pelletier, DanielAff4; Pozzilli, CarloAff11; Schippling, SvenAff12; Sousa, LiviaAff13; Traboulsee, AnthonyAff14; Uitdehaag, Bernard M. J.Aff15; Van Wijmeersch, BartAff16; Choudhry, ZiaAff17; Daizadeh, NadiaAff17; Singer, Barry A.Aff18 |
| Source: | CNS Drugs. 34(9):973-988 |
| Database: | Springer Nature Journals |